Drug Profile
Research programme: metabolic disorders/obesity therapeutics - Genfit/Servier
Alternative Names: SERX-1Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Genfit; Servier
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Metabolic disorders; Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-disorders in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in France
- 15 Apr 2010 Preclinical development is ongoing